Related Experiment Video

Updated: Jul 7, 2025

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.1K

Antibiotic treatment in cirrhotic patients

Marco Fiore1, Sebastiano Leone2

  • 1Department of Women, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples 80138, Italy. marco.fiore@hotmail.it.

World Journal of Clinical Cases
|December 22, 2023
PubMed

Insights

Third-generation cephalosporins are not recommended for empirical treatment of ascitic fluid infections in liver cirrhosis patients. Current data suggests alternative approaches are needed due to rising antibiotic resistance.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Clinical Microbiology

Background:

  • Bacterial infections are a frequent complication in patients with liver cirrhosis, with spontaneous bacterial peritonitis (SBP) being the most common.
  • The review by Liakina V highlights current data on bacterial complications and antibiotic resistance in this patient population.
  • Ascitic fluid infections, including SBP and bacterascites, pose significant challenges in managing liver cirrhosis patients.

Discussion:

  • This editorial questions the empirical use of third-generation cephalosporins for suspected SBP when ascitic fluid polymorphonuclear leukocytes (PMNs) exceed 250/mm³.
  • Bacterascites, defined by bacterial growth with PMNs < 250/mm³, shows comparable severity and prognosis to SBP in recent studies, indicating diagnostic and treatment complexities.
  • The prevalence of antibiotic-resistant isolates necessitates a re-evaluation of current treatment guidelines for ascitic fluid infections.

Key Insights:

  • Third-generation cephalosporins should not be the empirical treatment of choice for ascitic fluid infections in liver cirrhosis.
  • Bacterascites and SBP share similar clinical outcomes, underscoring the need for precise diagnosis and management.
  • Antibiotic resistance patterns demand updated therapeutic strategies to effectively treat infections in this vulnerable patient group.

Outlook:

  • Further research is needed to establish optimal diagnostic criteria and treatment protocols for all forms of ascitic fluid infections.
  • Development of novel therapeutic agents and antibiotic stewardship programs are crucial to combat resistance.
  • Clinical practice guidelines require revision based on current epidemiological data and emerging resistance trends.
Keywords:
BacterascitesCirrhosisEnd-stage liver diseaseMultidrug resistanceSpontaneous bacterial peritonitis

More Related Videos

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis03:42

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis

Published on: March 15, 2024

562
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.6K

Related Concept Videos

Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
181
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
128
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
411